Finally, a novel triple GLP1R/GCGR/GIPR agonist, HM15211, induced significant reductions in liver steatosis, fibrosis, and inflammation in mice [131]; a phase 2 clinical trial is ongoing (NCT04505436). Here, GCGR is linked to fatty liver disease.